Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. Waks AG, et al. Among authors: yang f. Clin Cancer Res. 2019 Aug 1;25(15):4644-4655. doi: 10.1158/1078-0432.CCR-19-0173. Epub 2019 May 6. Clin Cancer Res. 2019. PMID: 31061067 Free PMC article.
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Yang F, et al. Cancer Res. 2011 Aug 15;71(16):5512-21. doi: 10.1158/0008-5472.CAN-10-2614. Epub 2011 Jul 1. Cancer Res. 2011. PMID: 21724587 Free PMC article.
Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EA. Swisher SK, et al. Among authors: yang f. Ann Surg Oncol. 2016 Jul;23(7):2242-8. doi: 10.1245/s10434-016-5173-8. Epub 2016 Mar 10. Ann Surg Oncol. 2016. PMID: 26965699
Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.
Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D. Acharya S, et al. Among authors: yang f. Cancer Res. 2019 Aug 15;79(16):4211-4226. doi: 10.1158/0008-5472.CAN-18-3803. Epub 2019 Jun 25. Cancer Res. 2019. PMID: 31239273 Free PMC article.
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. Pairawan S, et al. Among authors: yang f. Breast Cancer Res. 2021 Mar 4;23(1):29. doi: 10.1186/s13058-021-01406-x. Breast Cancer Res. 2021. PMID: 33663585 Free PMC article.
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. Fujii T, et al. Among authors: yang f. Breast Cancer Res Treat. 2021 Sep;189(2):455-461. doi: 10.1007/s10549-021-06276-7. Epub 2021 Jun 15. Breast Cancer Res Treat. 2021. PMID: 34131830
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Yam C, et al. Among authors: yang f. Clin Cancer Res. 2021 Oct 1;27(19):5365-5375. doi: 10.1158/1078-0432.CCR-21-0144. Clin Cancer Res. 2021. PMID: 34253579 Free PMC article.
Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang F. Sun X, et al. Among authors: yang f. Mod Pathol. 2022 May;35(5):601-608. doi: 10.1038/s41379-021-00973-w. Epub 2021 Nov 27. Mod Pathol. 2022. PMID: 34839351 Free article.
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X. Zhang J, et al. Among authors: yang f, yang j. Clin Cancer Res. 2022 Feb 15;28(4):618-628. doi: 10.1158/1078-0432.CCR-21-2827. Clin Cancer Res. 2022. PMID: 34844975 Clinical Trial.
23,754 results
You have reached the last available page of results. Please see the User Guide for more information.